PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING AUTOIMMUNE DISEASE COMPRISING INTERLEUKIN-27 PROTEIN, IL-27-FC FUSION PROTEIN AND MUTANT THEREOF

摘要

A pharmaceutical composition, il-27-fc fusion proteins and its mutant containing interleukin-27 are provided to the production for effectively inhibiting IL-17 and by promoting the difference of Th-1 to increase the production of IFN-γ, in order to handle and prevent autoimmune diseases. One pharmaceutical composition of the treatment and prevention for autoimmune diseases includes interleukin-27, il-27-fc fusion proteins and its mutant. Interleukin-27 is people-derived protein. Pharmaceutical composition contains il-27-fc fusion proteins, and wherein the carboxyl terminal of interleukin-27 is coupled with the amino terminal of immunoglobulin Fc and peptide. Immunoglobulin Fc includes IgG, IgA, IgM, IgE and IgD. originating from a group being selected fromImmunoglobulin Fc has the hinge point that can have one or more cyophorin. Autoimmune diseases represent systemic lupus erythematosus, Sjogren syndrome, Hashimoto thyroiditis, rheumatoid arthritis, polymyositis, chorionitis, Addison disease, Leucoplakia, pernicious anaemia, glomerulonephritis or pulmonary fibrosis.